Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $48.2B | $15.2B | $7.1B | $12.8B | 38.2% | -0.2% | -178.8% |
| 2024 | $48.3B | $3.2B | $-8.9B | $13.9B | -54.8% | 7.3% | -211.5% |
| 2023 | $45.0B | $19.4B | $8.0B | $12.7B | 27.3% | -2.5% | 26.8% |
| 2022 | $46.2B | $19.2B | $6.3B | $11.9B | 20.4% | - | - |
| 2021 |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 46,159 | 45,006 | 48,300 | 48,195 |
| Operating Revenue | - | 45,413 | 44,386 | 47,257 | 47,203 |
| Cost Of Revenue | - | 10,137 | 10,693 | 13,968 | 13,936 |
| Gross Profit | - | 36,022 | 34,313 | 34,332 | 34,259 |
| Operating Expense | - | 26,918 | 26,118 | 28,445 | 20,535 |
| Research And Development | - | 9,509 | 9,299 | 11,159 | 9,951 |
| Selling General And Administration | - | 7,814 | 7,772 | 8,414 | 7,267 |
| Total Expenses | - | 37,055 | 36,811 | 42,413 | 34,471 |
| Operating Income | - | 9,104 | 8,195 | 5,887 | 13,724 |
| EBITDA | - | 19,221 | 19,366 | 3,168 | 15,230 |
| Normalized EBITDA | - | 21,414 | 20,239 | 17,100 | 19,945 |
| EBIT | - | 8,945 | 9,606 | -6,432 | 11,219 |
| Interest Expense | - | 1,232 | 1,166 | 1,947 | 1,891 |
| Net Interest Income | - | -1,232 | -1,166 | -1,947 | -1,891 |
| Other Non Operating Income Expenses | - | 2,034 | 2,284 | 1,613 | 2,211 |
| Other Income Expense | - | -159 | 1,411 | -12,319 | -2,504 |
| Interest Expense Non Operating | - | 1,232 | 1,166 | 1,947 | 1,891 |
| Net Non Operating Interest Income Expense | - | -1,232 | -1,166 | -1,947 | -1,891 |
| Pretax Income | - | 7,713 | 8,440 | -8,379 | 9,328 |
| Tax Provision | - | 1,368 | 400 | 554 | 2,272 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | -388.16 | -41.03 | -2,925.72 | -1,148.42 |
| Net Income Continuous Operations | - | 6,345 | 8,040 | -8,933 | 7,055 |
| Net Income From Continuing And Discontinued Operation | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Net Income From Continuing Operation Net Minority Interest | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Net Income | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Net Income Common Stockholders | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Net Income Including Noncontrolling Interests | - | 6,345 | 8,040 | -8,933 | 7,055 |
| Normalized Income | - | 8,131.84 | 8,856.97 | 2,058.28 | 10,620.58 |
| Diluted NI Availto Com Stockholders | - | 6,327 | 8,025 | -8,948 | 7,054 |
| Basic Average Shares | - | 2,130 | 2,069 | 2,027 | 2,034 |
| Diluted Average Shares | - | 2,146 | 2,078 | 2,027 | 2,039 |
| Reconciled Depreciation | - | 10,276 | 9,760 | 9,600 | 4,011 |
| Reconciled Cost Of Revenue | - | 9,456 | 9,980 | 13,240 | 13,242 |
| Total Unusual Items | - | -2,193 | -873 | -13,932 | -4,715 |
| Total Unusual Items Excluding Goodwill | - | -2,193 | -873 | -13,932 | -4,715 |
| Minority Interests | - | -18 | -15 | -15 | -2 |
| Special Income Charges | - | -1,563 | -1,162 | -14,426 | -5,225 |
| Gain On Sale Of Business | 9 | 211 | 0 | -15 | - |
| Other Special Charges | - | 444 | -390 | 84 | 434 |
| Impairment Of Capital Assets | 0 | 0 | 29 | 47 | - |
| Restructuring And Mergern Acquisition | - | 1,330 | 1,552 | 14,342 | 4,791 |
| Gain On Sale Of Security | - | -630 | 289 | 494 | 510 |
| Depreciation Amortization Depletion Income Statement | - | 9,595 | 9,047 | 8,872 | 3,317 |
| Depreciation And Amortization In Income Statement | - | 9,595 | 9,047 | 8,872 | 3,317 |
| General And Administrative Expense | 7,675 | 7,814 | - | - | - |
| Other Gand A | 7,690 | 7,814 | - | - | - |
| Salaries And Wages | -15 | - | - | - | - |
| Selling And Marketing Expense | 7,690 | 7,814 | - | - | - |
| Earnings From Equity Interest | 745 | -801 | -160 | - | - |
| Amortization | - | 9,595 | 9,047 | 8,872 | 3,317 |
| Amortization Of Intangibles Income Statement | - | 9,595 | 9,047 | 8,872 | 3,317 |
| Other Taxes | 0 | - | - | - | - |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Bristol-Myers Squibb Companythis co. | BMY | $115.6B | 16.39↓ discount | 6.26 | 38.2% | 10.01 |
| Pfizer Inc. | PFE | $146.4B | 18.84 | 1.69 | 9.0% | 12.47 |
| Danaher Corporation | DHR | $132.1B | 36.55 | 2.51 | 6.9% | 21.19 |
| CVS Health Corporation | CVS | $121.0B | 68.43 | 1.61 | 2.4% | 19.52 |
| Stryker Corporation | SYK | $115.5B |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| 35.57 |
| 5.15 |
| 14.5% |
| 20.16 |
| Vertex Pharmaceuticals Incorporated | VRTX | $112.1B | 28.36 | 6.01 | 21.2% | 22.41 |
| Medtronic plc | MDT | $105.2B | 22.56 | 2.19 | 9.7% | 14.26 |
| McKesson Corporation | MCK | $91.0B | 19.11 | -41.89 | -219.2% | 13.32 |
| Elevance Health, Inc. | ELV | $88.9B | 15.70 | 2.03 | 12.9% | - |
| Peer Median | - | 25.46 | 2.11 | 9.3% | 19.52 | |
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
Historically, Feb has averaged the highest return (+3.8%); Apr the lowest (-7.5%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.1%Positive MonthJan 2026: +2.06% | +13.3%Positive MonthFeb 2026: +13.30% | -2.8%Negative MonthMar 2026: -2.76% | -0.1%Neutral MonthApr 2026: -0.10% | -5.6%Negative MonthMay 2026: -5.63% | +0.8%Neutral MonthJun 2026: +0.77% | +13.3%Positive MonthJul 2026: +13.35% | +3.5%*Positive MonthAug 2026: +3.52% | — | — | — | — |
| 2025 | +4.2%Positive MonthJan 2025: +4.23% | +1.1%Neutral MonthFeb 2025: +1.14% | +2.3%Positive MonthMar 2025: +2.30% | -17.7%Negative MonthApr 2025: -17.69% | -3.8%Negative MonthMay 2025: -3.82% | -4.1%Negative MonthJun 2025: -4.12% | -6.4%Negative MonthJul 2025: -6.44% | +8.9%Positive MonthAug 2025: +8.94% | -4.4%Negative MonthSep 2025: -4.41% | +2.2%Positive MonthOct 2025: +2.15% | +6.8%Positive MonthNov 2025: +6.79% | +9.6%Positive MonthDec 2025: +9.63% |
| 2024 | -4.8%Negative MonthJan 2024: -4.76% | +3.8%Positive MonthFeb 2024: +3.85% | +6.9%Positive MonthMar 2024: +6.86% | -19.0%Negative MonthApr 2024: -18.97% | -6.5%Negative MonthMay 2024: -6.49% | +1.1%Neutral MonthJun 2024: +1.07% | +14.5%Positive MonthJul 2024: +14.52% | +5.0%Positive MonthAug 2024: +5.03% | +3.6%Positive MonthSep 2024: +3.58% | +7.8%Positive MonthOct 2024: +7.79% | +6.2%Positive MonthNov 2024: +6.19% | -4.5%Negative MonthDec 2024: -4.49% |
| 2023 | +1.0%Neutral MonthJan 2023: +0.97% | -5.1%Negative MonthFeb 2023: -5.08% | +0.5%Neutral MonthMar 2023: +0.51% | -3.7%Negative MonthApr 2023: -3.66% | -3.5%Negative MonthMay 2023: -3.49% | -0.8%Neutral MonthJun 2023: -0.76% | -2.8%Negative MonthJul 2023: -2.75% | -0.9%Neutral MonthAug 2023: -0.87% | -5.9%Negative MonthSep 2023: -5.86% | -11.2%Negative MonthOct 2023: -11.22% | -4.2%Negative MonthNov 2023: -4.17% | +3.9%Positive MonthDec 2023: +3.91% |
| 2022 | +4.1%Positive MonthJan 2022: +4.07% | +5.8%Positive MonthFeb 2022: +5.83% | +6.3%Positive MonthMar 2022: +6.35% | +3.1%Positive MonthApr 2022: +3.07% | +0.2%Neutral MonthMay 2022: +0.24% | +2.1%Positive MonthJun 2022: +2.05% | -4.2%Negative MonthJul 2022: -4.18% | -8.6%Negative MonthAug 2022: -8.63% | +5.5%Positive MonthSep 2022: +5.46% | +9.0%Positive MonthOct 2022: +8.97% | +3.6%Positive MonthNov 2022: +3.63% | -10.4%Negative MonthDec 2022: -10.38% |
| 2021 | — | — | — | — | +5.3%Positive MonthMay 2021: +5.29% | +1.7%Neutral MonthJun 2021: +1.67% | +1.6%Neutral MonthJul 2021: +1.57% | -1.5%Neutral MonthAug 2021: -1.49% | -11.5%Negative MonthSep 2021: -11.50% | -1.3%Neutral MonthOct 2021: -1.30% | -8.2%Negative MonthNov 2021: -8.17% | +16.3%Positive MonthDec 2021: +16.26% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 6 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
